Founded in Texas in 2014, Exos Aerospace is a private company that is rapidly developing into a highly capable launch services provider. It is building on its current suborbital plans to enable the deployment of payloads into low Earth orbit (LEO) in the next three years. This should allow the company to become a cost-effective launch partner for smaller payloads, as well as a transportation and logistics supplier for future space manufacturing and research projects.
Written by
Exos Aerospace |
Developing reusable launch vehicles
|
SpaceTech – launch services |
QuickView
26 April 2022 |
Funding rounds 1–9, 2014 to 2022
Share details
Business description
Bull
Bear
Analyst
|
|||||||||||||||||||||||||||
Founded in Texas in 2014, Exos Aerospace is a private company that is rapidly developing into a highly capable launch services provider. It is building on its current suborbital plans to enable the deployment of payloads into low Earth orbit (LEO) in the next three years. This should allow the company to become a cost-effective launch partner for smaller payloads, as well as a transportation and logistics supplier for future space manufacturing and research projects.
Developing low-cost reusable space transport
Exos Aerospace’s ambition is to build and fly LEO capable reusable rockets while enabling other innovations in world-leading technologies in sectors such as healthcare. While working with both governmental and commercial customers, Exos is driving down the cost to deploy payloads to levels that provide access even to high school science departments. The company integrates proven technologies, many developed by NASA using a design, build, test, iterate (DBTI) philosophy, which provides excellence in prototype systems development. To date, the company has designed and developed hundreds of rocket engines and dozens of launch vehicles, both Suborbital Reusable Launch Vehicles (sRLVs) and vertical takeoff, vertical landing (VTVL). In addition, Exos has integrated reliable propulsion systems into crewed rocket-powered aircraft and successfully demonstrated hundreds of inflight relights.
Flight test programme key to progress
Following four flight tests of its SARGE Mk1 (Suborbital Autonomous Rocket with GuidancE) sRLV, which suffered various setbacks, the company is building a second system (SARGE Mk2) for test flight. In February 2022, the Federal Aviation Administration (FAA) issued a revision to Exos’s Commercial Space Transportation License, extending for two years its permit to carry out pre-flight ground operations and sRLV missions from Spaceport America. While no date is available for Sarge 2’s initial qualification test flight, success should allow it to apply for an indefinite delivery, indefinite quantity (IDIQ) contract as a flight services provider under NASA’s $25m pa Research, Development, Demonstration, and Infusion programme. Meanwhile, the company is developing its Jaguar two-stage vehicle programme for orbital payloads up to around 200kg with a reusable first stage.
Preparing the organisation for growth
Exos Aerospace plans to move its Greenville-based operations to McKinney, Texas as it seeks to enter the commercial orbital market, employing several hundred more staff. It has also formed a National Charter Enterprise in Italy, Exos Aerospace Italia, to develop systems and missions compliant with International Traffic in Arms Regulations.
EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
|
Research: Healthcare
Diurnal has announced the extension of its existing marketing and distribution agreement with EffRx Pharmaceuticals, to include Efmody (in addition to Alkindi) in Switzerland. The agreement is in line with Diurnal’s strategy to leverage Alkindi’s supply chain and distribution network for Efmody and we expect more such agreements in the near future. After filing a market authorisation application (MAA) to Swissmedic in H222, EffRx expects the product to be launched in 2024. Further, on 20 April Diurnal announced that it has extended its marketing agreement (for Alkindi and Efmody) with Er-Kim to add Greece, Cyprus and Malta to the existing markets (Turkey, Romania and Bulgaria).